organic papers

Acta Crystallographica Section E Structure Reports Online

ISSN 1600-5368

Pei-Liang Zhao

Key Laboratory of Pesticides and Chemical Biology of the Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, People's Republic of China

Correspondence e-mail: peiliangzhao1999@yahoo.com.cn

Key indicators

Single-crystal X-ray study T = 292 KMean $\sigma(\text{C}-\text{C}) = 0.005 \text{ Å}$ R factor = 0.055 wR factor = 0.181 Data-to-parameter ratio = 15.7

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

3-(4,6-Dimethylpyrimidin-2-ylsulfanyl)-2,2-dimethylchroman-4-one

In the title compound, $C_{17}H_{18}N_2O_2S$, the six-membered heterocyclic ring of the chromanone unit adopts a half-chair conformation. The crystal structure is stabilized by intermolecular $C-H\cdots\pi$ and $\pi-\pi$ interactions.

Received 2 December 2006 Accepted 14 December 2006

Comment

4-Chromanone derivatives are well known to exhibit a wide spectrum of biological activities, including antiviral, anticancer and antibiotic properties (Cho *et al.*, 1996). In addition, pyrimidine derivatives also have good biological activities (Wang *et al.*, 1995). These findings prompted us to synthesize a new series of chromanone derivatives by incorporating pyrimidine at the 3-position, in the hope of finding better bioactive molecules. We present here the X-ray crystallographic analysis of the title compound, (I), which was designed and synthesized in our laboratory.



The six-membered heterocyclic ring of the chromanone unit of (I) adopts a half-chair conformation (Fig. 1). The pyrimidine ring and the chromanone unit are twisted; the benzene ring makes a dihedral angle of $82.02 (2)^{\circ}$ with the pyrimidine ring.

The crystal packing of (I) is consolidated by intermolecular $C-H\cdots\pi$ interactions (Table 1; *Cg*1 and *Cg*2 are the centroids of the benzene and pyrimidine rings, respectively) and a $\pi-\pi$ stacking interaction between adjacent pyrimidine rings related by an inversion centre. The centroid-to-centroid and interplanar distances are 3.462 (2) and 3.282 (2) Å, respectively (Fig. 2).

Experimental

A mixture of 4,6-dimethylpyrimidine-2-thiol (2.0 mmol), acetone (20 ml) and anhydrous potassium carbonate (2.1 mmol) was refluxed for 1 h and then 3-bromo-2,2-dimethylchroman-4-one (2.0 mmol) was added dropwise. After refluxing the mixture for 3 h, the resultant precipitate was filtered off and washed with acetone. The residue was purified by column chromatography on silica gel with hexane–diethyl ether (10:1 ν/ν) as eluent to afford (I) (yield 76%, m.p. 437 K). ¹H NMR (CDCl₃, δ , p.p.m.): 7.90 (*d*, 1H, C14-H), 7.51 (*t*, 1H, C13-H),

© 2007 International Union of Crystallography All rights reserved 7.02 (*m*, 2H, C11-H, C12-H), 6.72 (*s*, 1H, C4-H), 5.38 (*s*, 1H, C7-H), 2.41 (*s*, 6H, C16-H, C17-H), 1.66 (*s*, 3H, C5-H), 1.50 (*s*, 3H, C3-H). Crystals of (I) suitable for X-ray diffraction were grown from a methanol solution at 292 K.

V = 828.1 (2) Å³

 $D_x = 1.261 \text{ Mg m}^{-3}$

Mo $K\alpha$ radiation

Block, colourless

 $0.30 \times 0.20 \times 0.04~\text{mm}$

3191 independent reflections

1955 reflections with $I > 2\sigma(I)$

H-atom parameters constrained

 $w = 1/[\sigma^{2}(F_{o}^{2}) + (0.1018P)^{2}]$ where $P = (F_{o}^{2} + 2F_{c}^{2})/3$

 $(\Delta/\sigma)_{\rm max} = 0.002$

 $\Delta \rho_{\rm max} = 0.40 \text{ e} \text{ Å}^{-3}$

 $\Delta \rho_{\rm min} = -0.18 \text{ e } \text{\AA}^{-3}$

 $\mu = 0.20 \text{ mm}^{-1}$

T = 292 (2) K

 $R_{\rm int} = 0.035$

 $\theta_{\rm max} = 26.0^\circ$

Z = 2

Crystal data

 $\begin{array}{l} C_{17}H_{18}N_2O_2S\\ M_r = 314.39\\ \text{Triclinic, }P\overline{1}\\ a = 8.3523 \; (12) \text{ Å}\\ b = 9.1835 \; (13) \text{ Å}\\ c = 11.4241 \; (16) \text{ Å}\\ \alpha = 92.954 \; (2)^{\circ}\\ \beta = 99.926 \; (3)^{\circ}\\ \gamma = 105.329 \; (2)^{\circ} \end{array}$

Data collection

Bruker SMART 4K CCD areadetector diffractometer φ and ω scans Absorption correction: none 4725 measured reflections

Refinement

Refinement on F^2 $R[F^2 > 2\sigma(F^2)] = 0.055$ $wR(F^2) = 0.181$ S = 0.973191 reflections 203 parameters

Table 1

Hydrogen-bond geometry (Å, °).

D-H	$H \cdot \cdot \cdot A$	$D \cdots A$	$D - H \cdot \cdot \cdot A$
0.98	2.28	2.905 (3)	121
0.96	2.80	3.216 (4)	107
0.96	2.97	3.614 (4)	125
0.93	2.89	3.702 (4)	146
	<i>D</i> —H 0.98 0.96 0.96 0.93	D−H H···A 0.98 2.28 0.96 2.80 0.96 2.97 0.93 2.89	$D-H$ $H \cdots A$ $D \cdots A$ 0.982.282.905 (3)0.962.803.216 (4)0.962.973.614 (4)0.932.893.702 (4)

Symmetry codes: (i) -x + 2, -y + 2, -z + 1; (ii) x, y - 1, z.

H atoms were initially located in a difference Fourier map. Methyl H atoms were then constrained to an ideal geometry, with C–H = 0.96 Å and $U_{iso}(H) = 1.5U_{eq}(C)$, but each group was allowed to rotate freely about its C–C bond. Other H atoms were placed in geometrically idealized positions, with C–H = 0.93–0.98 Å, and refined as riding, with $U_{iso}(H) = 1.2U_{eq}(C)$.

Data collection: *SMART* (Bruker, 2001); cell refinement: *SAINT-Plus* (Bruker, 2001); data reduction: *SAINT-Plus*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Bruker, 2001); software used to prepare material for publication: *SHELXTL*.



Figure 1

The molecular structure of (I), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.



Figure 2

A partial packing diagram of (I), showing intermolecular C-H··· π (dashed lines) and π - π stacking interactions.

The author acknowledges financial support from the National Key Project for Basic Research (grant No. 2002CCA00500), the National Natural Science Foundation of China (grant Nos. 20432010, 20476036 and 20172017), the Programme for New Century Excellent Talents in Chinese Universities of China, and the Programme for Excellent Research Group of Hubei Province (grant No. 2004ABC002).

References

- Bruker (2001). SAINT-Plus (Version 6.45), SMART (Version 5.628) and SHELXTL (Version 5.10). Bruker AXS Inc., Madison, Wisconsin, USA.
- Cho, H., Katoh, S., Sayama, S., Murakami, K., Nakanishi, H., Kajimoto, Y., Ueno, H., Kawasaki, H., Aisaka, K. & Uchida, I. (1996). J. Med. Chem. 39, 3797–3805.
- Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.
- Wang, G. T., Li, S., Wideburg, N., Krafft, G. A. & Kempf, D. J. (1995). J. Med. Chem. 38, 2995–3002.